Literature DB >> 10024332

Aldosterone excretion rate and blood pressure in essential hypertension are related to polymorphic differences in the aldosterone synthase gene CYP11B2.

E Davies1, C D Holloway, M C Ingram, G C Inglis, E C Friel, C Morrison, N H Anderson, R Fraser, J M Connell.   

Abstract

Significant correlation of body sodium and potassium with blood pressure (BP) may suggest a role for aldosterone in essential hypertension. In patients with this disease, the ratio of plasma renin to plasma aldosterone may be lower than in control subjects and plasma aldosterone levels may be more sensitive to angiotensin II (Ang II) infusion. Because essential hypertension is partly genetic, it is possible that altered control of aldosterone synthase gene expression or translation may be responsible. We compared the frequency of 2 linked polymorphisms, one in the steroidogenic factor-1 (SF-1) binding site and the other an intronic conversion (IC), in groups of hypertensive and normotensive subjects. In a larger population, the relationship of aldosterone excretion rate to these polymorphisms was also evaluated. In 138 hypertensive subjects, there was a highly significant excess of TT homozygosity (SF-1) over CC homozygosity compared with a group of individually matched normotensive control subjects. The T allele was significantly more frequent than the C allele in the hypertensive group compared with the control group. Similarly, there was a highly significant relative excess of the conversion allele over the "wild-type" allele and of conversion homozygosity over wild-type homozygosity in the hypertensive group compared with the control group. In 486 subjects sampled from the North Glasgow Monitoring of Trends and Determinants in Cardiovascular Disease (MONICA) population, SF-1 and IC genotypes were compared with tetrahydroaldosterone excretion rate. Subjects with the SF-1 genotypes TT or TC had significantly higher excretion rates than those with the CC genotype. The T allele was associated with higher excretion rates than the C allele. However, no significant differences were found in excretion rate between subjects of different IC genotype. Urinary aldosterone excretion rate may be a useful intermediate phenotype linking these genotypes to raised BP. However, no causal relationship has yet been established, and it is possible that the polymorphisms may be in linkage with other causative mutations.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10024332     DOI: 10.1161/01.hyp.33.2.703

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  27 in total

Review 1.  Primary aldosteronism: rare bird or common cause of secondary hypertension?

Authors:  M Stowasser
Journal:  Curr Hypertens Rep       Date:  2001-06       Impact factor: 5.369

Review 2.  Drug-gene interactions between genetic polymorphisms and antihypertensive therapy.

Authors:  Hedi Schelleman; Bruno H Ch Stricker; Anthonius De Boer; Abraham A Kroon; Monique W M Verschuren; Cornelia M Van Duijn; Bruce M Psaty; Olaf H Klungel
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 3.  Mechanisms of hypertension: the expanding role of aldosterone.

Authors:  E Marie Freel; John M C Connell
Journal:  J Am Soc Nephrol       Date:  2004-08       Impact factor: 10.121

4.  Interaction between the C(-344)T polymorphism of CYP11B2 and alcohol consumption on the risk of essential hypertension in a Chinese Mongolian population.

Authors:  Xing-Qiang Pan; Yong-Hong Zhang; Yong-Yue Liu; Wei-Jun Tong
Journal:  Eur J Epidemiol       Date:  2010-09-29       Impact factor: 8.082

5.  The renin-angiotensin-aldosterone system in cerebral small vessel disease.

Authors:  David Brenner; Julien Labreuche; Fernando Pico; Philip Scheltens; Odette Poirier; François Cambien; Pierre Amarenco
Journal:  J Neurol       Date:  2008-05-02       Impact factor: 4.849

6.  Genetic variation in aldosterone synthase predicts plasma glucose levels.

Authors:  K Ranade; K D Wu; N Risch; M Olivier; D Pei; C F Hsiao; L M Chuang; L T Ho; E Jorgenson; R Pesich; Y D Chen; V Dzau; A Lin; R A Olshen; D Curb; D R Cox; D Botstein
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-30       Impact factor: 11.205

Review 7.  Hypertension and the expanding role of aldosterone.

Authors:  Scott M Mackenzie; John Connell
Journal:  Curr Hypertens Rep       Date:  2006-06       Impact factor: 5.369

Review 8.  Genetics of the mineralocorticoid system in primary hypertension.

Authors:  Paolo Ferrari
Journal:  Curr Hypertens Rep       Date:  2002-02       Impact factor: 5.369

Review 9.  Aldosterone and arterial hypertension.

Authors:  Andreas Tomaschitz; Stefan Pilz; Eberhard Ritz; Barbara Obermayer-Pietsch; Thomas R Pieber
Journal:  Nat Rev Endocrinol       Date:  2009-12-22       Impact factor: 43.330

Review 10.  Gene markers and antihypertensive therapy.

Authors:  Stephen T Turner; Gary L Schwartz
Journal:  Curr Hypertens Rep       Date:  2005-02       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.